APA Practice Guidelines
C. Maintenance Treatment of Bipolar Disorder
cont. from
Maintenance
medication treatment is generally recommended following a single
manic episode. Although few studies have been conducted involving patients with
bipolar II disorder, consideration of maintenance treatment for this form of the
illness is also warranted. Primary goals of treatment include relapse
prevention, reduction of subthreshold symptoms, and reduction of suicide risk.
Goals also need to include reduction of cycling frequency and mood instability
as well as improvement in overall functioning. Pharmacotherapy must be employed
in ways that yield good tolerability and do not predispose the patient to
nonadherence.
Options with the best empirical evidence to support their use as maintenance
treatments include lithium or
valproate; possible alternatives include
lamotrigine,
carbamazepine, or oxcarbazepine. Despite limited data,
oxcarbazepine is included-as it was for acute treatment of mania-because its
efficacy may be similar to that of carbamazepine but with better tolerability.
In general, if one of these medications was used to achieve remission from the
most recent depressive or manic episode, it should be continued. Maintenance ECT
may also be considered for patients whose acute episode responded to ECT.
Selection of the initial treatment should be guided by clinical factors such as
illness severity, by associated features (e.g., rapid cycling, psychosis), and
by patient preference, with particular attention to side effect profiles.
For patients treated with an antipsychotic medication during the preceding
acute episode, the need for ongoing antipsychotic treatment should be reassessed
upon entering the maintenance phase. Since antipsychotic agents, particularly
typical
antipsychotics, may cause tardive dyskinesia with long-term use,
antipsychotics should be slowly tapered and discontinued unless they are
required to control persistent psychosis or provide prophylaxis against
recurrence. While maintenance therapy with atypical antipsychotics may be
considered, there is as yet no definitive evidence that their efficacy in
maintenance is comparable to that of agents such as lithium or valproate.
Patients with bipolar disorder are likely to gain some additional benefit
during the maintenance phase from a concomitant psychosocial intervention that
addresses illness management (i.e., adherence, lifestyle changes, and early
detection of prodromal symptoms) and interpersonal difficulties. Although not
adequately studied to provide evidence-based documentation, supportive and
psychodynamic psychotherapy are widely used in addition to medication.
Group psychotherapy, in conjunction with appropriate medication, may also
help patients address such issues as adherence to a treatment plan, adaptation
to a chronic illness, regulation of self-esteem, and management of marital as
well as other psychosocial issues.
Support groups provide useful information about bipolar disorder and its
treatment. Patients in these groups often benefit from hearing the experiences
of others who are struggling with such issues as denial versus acceptance of the
need for medication, problems with side effects, and how to shoulder other
burdens associated with the illness and its treatment. Advocacy groups such as
the National Depressive and Manic-Depressive Association and the National
Alliance on Mental Illness (Appendix I) have many local chapters that provide
both support and educational material to patients and their families.
Although maintenance medication combinations are often associated with
increases in side effects, use of such regimens should be considered for
patients who have not responded adequately to simpler regimens. The addition of
another maintenance medication, an atypical antipsychotic, or an antidepressant
may be necessary for patients who experience either continuing high levels of
subthreshold symptoms or a breakthrough episode of illness. There are currently
insufficient data to support one combination over another. Maintenance ECT may
also be considered for patients whose acute episode responded to ECT.
next: Special Clinical Features
Influencing the Treatment Plan
top .
pages 1
2
3
4
5
6 7 .
send to friend .
bipolar site
map
Written 4/02. Reviewed: 03/2006
|